NCT00144053View on ClinicalTrials.gov

A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

April 30, 2001

Conditions
Lung Cancer
Interventions
DRUG

Cisplatin+Vindesine+MMC/ concurrent radiation

DRUG

Irinotecan+Carboplatin/concurrent radiation

DRUG

Paclitaxel+Carboplatin/concurrent radiation

All Listed Sponsors
lead

West Japan Thoracic Oncology Group

OTHER

NCT00144053 - A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter